Track record · closed signal

Gilead Sciences, Inc. (GILD) — closed signal from January 25, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 25, 2026.

Predicted vs. what happened

GILD price · publication thesis → realized outcomesplit-adjusted

$133.00 – $137.00Entry zone — fair-value band

$135.93Published — price the day we called it

$149.52Target — the price the thesis aimed for

$157.29Peak — highest point inside the window, not a realized return

$130.40Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 11 days.

Peak price

$157.29

peak on February 11, 2026 — not a realized return

Peak gain

+15.7%

peak, from the publication price

Window close

$130.40

end-of-window price, context only

Days to target

Window

January 25, 2026 – April 25, 2026

The thesis — published January 25, 2026

Predicted growth

+10%

over the measurement window

Target price

$149.52

the price the thesis aimed for

Entry zone

$133.00 – $137.00

the fair-value band we waited for

Price at publication

$135.93

published January 25, 2026

Confidence

76%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Gilead just had clear, positive clinical news that put its cancer drug Trodelvy back in the spotlight. That kind of company-specific update often drives attention and price moves for a few weeks to a few months. Treat this as a momentum trade: buy when the price falls into the entry zone and avoid chasing big jumps after headlines.

Primary drivers

Positive Phase 3 results keep Trodelvy in focus
Pipeline wins can lift how the market values the company
Healthcare catalysts reduce reliance on hot tech themes
Research deals extend the drug-development story

How it played out

GILD: target reached in 11 days

Lyra published GILD on 2026-01-25 at $135.93, with an entry zone of $133 to $137 and expected growth of 10%. The target was $149.52. The thesis pointed to positive Phase 3 results for Trodelvy, possible pipeline re-rating, less reliance on hot tech themes, and research deals extending the drug-development story.

Inside the window, GILD reached a peak of $157.29 on 2026-02-11. That was above the target, with a peak gain of 15.7%, and the target was reached in 11 days. By 2026-04-25, it had ended at $130.40. The thesis played out early, then the price gave back the move.

What happened during the window

On February 23, 2026, Gilead agreed to buy Arcellx in a deal valued at $7.8 billion. On April 7, 2026, Gilead agreed to buy Tubulis for $3.15 billion, with up to $1.85 billion in milestone payments.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All GILD signals